Bullish indicating open at $55-$60, IPO prices at $37
Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), recently reported the sale of company stock valued at approximately $556,590. According to a filing with the Securities and Exchange Commission, Timothy sold a total of 12,500 shares on March 5, 2025. The shares were sold at prices ranging from $44.401 to $44.9 per share. The transaction comes as AKRO shares have declined 11% over the past week, though they remain up 65% over the last six months. InvestingPro data shows the $3.4 billion biotech company is trading slightly above its Fair Value.
In addition to the sale, Timothy exercised stock options to acquire 12,500 shares at a price of $21.1 per share, which totaled $263,750. Following these transactions, Timothy holds 170,237 shares of Akero Therapeutics directly. According to InvestingPro analysis, the company maintains strong financial health with a current ratio of 19.4x and more cash than debt on its balance sheet. Analysts remain bullish on the stock, with price targets ranging from $60 to $109 per share.
These transactions were conducted under a pre-established Rule 10b5-1 trading plan, which allows company insiders to set up a schedule for selling stocks they own through an agreement made at a time when they do not possess any material nonpublic information. For deeper insights into AKRO’s insider trading patterns and 10+ additional ProTips, visit InvestingPro.
In other recent news, Akero Therapeutics has seen a series of updates from various analysts concerning its stock price targets, primarily driven by promising data from its treatment candidate, efruxifermin (EFX), for non-alcoholic steatohepatitis (NASH) and metabolic-associated steatohepatitis (MASH). Citi raised its price target for Akero Therapeutics to $80, noting the significant milestone achieved in the 96-week SYMMETRY study, which showed statistically significant fibrosis improvement in patients with compensated cirrhosis. Jefferies also increased its price target to $75, citing the company’s potential to capture a substantial opportunity in the NASH market due to strong trial data and reduced risk. Similarly, H.C. Wainwright and Canaccord Genuity raised their price targets to $72 and $73, respectively, while maintaining Buy ratings, reflecting confidence in the potential market value of EFX.
The analysts highlighted the positive trial results and the potential for EFX to become a foundational treatment for cirrhotic MASH patients. H.C. Wainwright’s analysis projects market exclusivity for EFX through 2037, with key risks identified including trial failures or safety issues. Jefferies emphasized the company’s attractiveness as an acquisition target due to its promising data and lack of major competition. The positive outlook from these firms underscores the anticipated growth in the MASH treatment market and the strategic interest Akero Therapeutics is expected to attract. These recent developments have contributed to an optimistic forecast for Akero’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.